Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. [electronic resource]
Producer: 20131230Description: 523-30 p. digitalISSN:- 1463-1326
- Adolescent
- Adult
- Aged
- Asian People
- Blood Glucose -- drug effects
- Diabetes Mellitus, Type 2 -- blood
- Dipeptidyl-Peptidase IV Inhibitors -- therapeutic use
- Double-Blind Method
- Fasting
- Female
- Glucagon-Like Peptide 1 -- drug effects
- Glucose Tolerance Test
- Glycated Hemoglobin -- drug effects
- Humans
- Hypoglycemic Agents -- therapeutic use
- Male
- Metformin -- therapeutic use
- Middle Aged
- Piperidones -- therapeutic use
- Pyrazines -- therapeutic use
- Pyrimidines -- therapeutic use
- Republic of Korea -- epidemiology
- Risk Reduction Behavior
- Sitagliptin Phosphate
- Treatment Outcome
- Triazoles -- therapeutic use
No physical items for this record
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.